All In Biotech

NDA 202439 · Janssen Pharms

Xarelto

Rivaroxaban · Oral

Last checked: Nov 20, 2026Latest source record: Mar 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Nov 4, 2011

Approved uses

5

Original approval plus efficacy supplements

Registered trials

419

129 Phase 3, 75 recruiting

FAERS reports

208,599

174,869 serious, 27,259 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 23, 2021 Supplement 35 · Efficacy LetterLabelReview
  • Mar 10, 2020 Supplement 31 · Efficacy LetterLabel
  • Oct 11, 2018 Supplement 25 · Efficacy Label
  • May 6, 2016 Supplement 17 · Efficacy LabelLetter
  • Nov 4, 2011 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval ReviewLabelLetter
4 products under this application
  • XARELTO · RIVAROXABAN 20MG · TABLET, ORAL · Prescription
  • XARELTO · RIVAROXABAN 10MG · TABLET, ORAL · Prescription
  • XARELTO · RIVAROXABAN 2.5MG · TABLET, ORAL · Prescription
  • XARELTO · RIVAROXABAN 15MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rivaroxaban" as an intervention, any sponsor and status, largest first.

All 419 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • gastrointestinal haemorrhage21,673
  • off label use8,056
  • haemorrhage7,819
  • dyspnoea7,421
  • epistaxis6,806
  • fatigue6,801
  • death6,190
  • fall6,184
  • pulmonary embolism6,046
  • drug ineffective6,005
  • diarrhoea5,790
  • anaemia5,772

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20074
20083
200952
201055
2011503
20123,861
20137,368
20149,409
201527,674
201629,714
201722,442
201821,010
201921,502
202014,671
202110,008
202210,492
20239,332
20248,319
20257,035
20265,145

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xarelto (Rivaroxaban)

2024 spending

$6.23B

Beneficiaries

1,321,019

6,660,246 claims

Per beneficiary

$4,718

$17.68 per unit

View as table
YearSpending
2020$4,701,314,805
2021$5,225,547,772
2022$5,772,682,548
2023$6,309,246,823
2024$6,232,231,840

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,278 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.